IL6 and atherosclerosis: These findings, alongside a broader body of evidence implicating inflammation in cardiovascular disease, have provided the rationale for ongoing Phase III clinical trials targeting IL‐6 signaling in atherosclerosis (ClinicalTrials.gov ID NCT05021835) [24, 25].